Pharmacovigilance Training Saudi Arabia: Internationally-Recognised Training for the Vision 2030 Biotech Era
Pharmacovigilance Training Saudi Arabia: Internationally-Recognised Training for the Vision 2030 Biotech Era
A live, UK-delivered pharmacovigilance programme for Saudi pharmacists and healthcare graduates who want to move into industry drug safety. Built on the same Good Pharmacovigilance Practices that the Saudi Food and Drug Authority's own guideline follows, and structured around 200 real-shape Individual Case Safety Reports processed before you apply for your first industry role.
Programme Length
6 months
Alongside your current role
Biotech Jobs Target
11,000 by 2030
55,000 by 2040, National Biotechnology Strategy
SFDA Requirement
PV staff in KSA
Local QPPV and Deputy must reside in the Kingdom
Live Format
Riyadh evening
UK evening sessions, recordings provided
Why Saudi pharmacists are looking at pharmacovigilance now
In January 2024 the Kingdom launched its National Biotechnology Strategy, with a clear ambition: to become the leading biotechnology hub in the Middle East and North Africa by 2030, and a global one by 2040. The targets attached to it are specific. Around 11,000 quality jobs by 2030, rising to around 55,000 by 2040, and a cumulative contribution of SAR 130 billion to the economy. The four priority areas are vaccines, biomanufacturing and localisation, genomics, and plant optimisation.
Here is the part that rarely makes the headlines. Every medicine that is made, licensed or marketed in the Kingdom carries a pharmacovigilance obligation for as long as it is on the market. More local manufacturing, more biologics and more vaccines mean more safety systems, more case reports, more aggregate reports and more inspections. Pharmacovigilance is not a side effect of the biotech strategy. It is one of the functions the strategy cannot run without.
Which leaves a practical question for a Saudi pharmacist or healthcare graduate reading this. If you want to move from hospital or community pharmacy into an industry drug safety role, at a multinational's Saudi entity, a national manufacturer or one of the new biomanufacturing ventures, how do you train to the standard those employers actually hire against?
The SFDA framework, in plain terms
The Saudi Food and Drug Authority's Guideline on Good Pharmacovigilance Practices was updated to version 4.0 in August 2025. It is organised into modules that mirror the European Union's GVP: pharmacovigilance systems, risk management plans, safety communication, risk minimisation and the rest. If you learn pharmacovigilance to EU GVP and ICH standards, you are learning the structure the SFDA guideline is built on.
Two requirements in that guideline matter directly to your career:
- Every marketing authorisation holder must have a local Qualified Person for Pharmacovigilance who works full time and resides in the Kingdom, registered through the Saudi Vigilance platform together with their pharmacovigilance training certificates and qualifications.
- Every marketing authorisation holder must also have a Deputy QPPV who resides in the Kingdom, and the guideline states this person should preferably be a Saudi citizen.
Read those two lines together and the opportunity is plain. The regulation itself asks for pharmacovigilance professionals who live in Saudi Arabia, and it names Saudi citizens as the preference for the deputy role. Those senior positions are filled from people who first learned case processing, aggregate reporting and signal work properly. The route in starts with the foundations.
What pharmacovigilance work looks like in a Saudi industry role
| Work area | What you do | How often |
|---|---|---|
| Individual Case Safety Report processing | Receive a report of a suspected adverse drug reaction, triage it for seriousness and expectedness, enter it into the safety database, code the events in MedDRA, write the case narrative and assess causality. | The core of most entry-level drug safety roles |
| Regulatory reporting to the SFDA | Identify cases that meet expedited reporting criteria and submit them through the Saudi Vigilance system within the required timelines. | Continuous, against a fixed regulatory clock |
| Aggregate reports and signal management | Contribute to Periodic Safety Update Reports and Periodic Benefit-Risk Evaluation Reports, and help detect emerging safety signals across the case base. | Around scheduled reporting cycles |
| Local pharmacovigilance system support | Support the local QPPV and Deputy QPPV with the day-to-day operation of the Saudi pharmacovigilance system, including inspection readiness. | Continuous |
The discipline is structured clinical assessment under a regulatory deadline. If you have reported an adverse drug reaction from a hospital ward or a community pharmacy, you have already stood at the start of this process. Industry pharmacovigilance is what happens to that report next.
Who hires pharmacovigilance professionals in Saudi Arabia
| Employer type | Examples | Typical entry route |
|---|---|---|
| Saudi entities of multinational pharmaceutical companies | The Riyadh and Jeddah operations of the global pharmaceutical groups | Drug Safety Officer or PV Specialist roles supporting the local QPPV. Strongest onward progression. |
| National manufacturers | SPIMACO, Tabuk Pharmaceuticals, and regional manufacturers with Saudi operations | Drug safety roles, often with broader scope earlier in your career. |
| Biomanufacturing and biotech ventures | The new vaccine, biologics and contract manufacturing ventures created under the National Biotechnology Strategy | Safety and quality roles built from the ground up, with room to grow with the organisation. |
| Contract research and pharmacovigilance service providers | CROs and specialist PV providers serving the Saudi and wider GCC market | High case volume, which builds experience quickly. |
Across all four, the question that turns a CV into an interview is the same: can this candidate show that they have already processed cases to an industry standard? Clinical credibility gets you read. Worked evidence gets you shortlisted.
Transferable skills you already have
| Your current experience | How it reads to an industry hiring manager |
|---|---|
| Hospital or clinical pharmacy | Medication review, adverse drug reaction recognition and clinical documentation. A direct precursor to case work. |
| Community pharmacy | Daily exposure to medicines, dosing, interactions and patient-reported problems. Foundational for event coding and causality. |
| Reporting adverse reactions to the Saudi Vigilance system | You have already seen the system from the reporter's side. Industry pharmacovigilance is the other side of the same process. |
| SCFHS registration and continuing education | Evidence that you work within a defined regulatory framework, which is exactly how industry pharmacovigilance operates. |
| Clinical English | The industry operates in English. Clinical-level fluency is the working standard. |
If you are still deciding whether this is the right direction, How to Get Into Pharmacovigilance sets out the full route, and AI in Pharmacovigilance Case Processing answers the question most people ask next: whether automation will take the role. If you are based in the Emirates, the UAE edition of this guide covers the Emirates Drug Establishment framework.
A realistic timeline
The programme runs for 6 months alongside your current role, so you change jobs only once an offer is signed. The months break down simply:
| Stage | What you are doing | What you have at the end |
|---|---|---|
| Phase 1 | Foundations: GVP, ICH definitions, seriousness criteria, MedDRA coding, case narratives and the reporting timelines. | Fluency with the case lifecycle and the frameworks the SFDA guideline is built on. |
| Phase 2 | Signal management, aggregate reporting and inspection readiness, working inside the VIGILANT IQ™ safety database environment. | A worked portfolio built around 200 real-shape cases that a Riyadh hiring manager can actually review. |
| Applications | CV repositioning, target employer list and interview preparation. | An industry-ready CV that translates your clinical experience into pharmacovigilance language. |
The bottleneck is almost never knowledge. Candidates who stall at the application stage usually apply without ever having processed a case to standard. Industry employers hire on portfolio evidence. That is the gap this programme is designed to close.
The PharmaLink Pharmacovigilance Programme
Phase 1 builds the case-processing foundations: GVP-aligned ICSR intake, MedDRA coding, narrative writing, seriousness and causality assessment. Phase 2 adds signal management, aggregate reporting and inspection readiness. 6 months across the two phases of the Full PV Pathway, built around the 200-case model. Work is marked Met Standard or Not Met Standard, with Distinction and Merit awarded where earned. The NOVATRA™ capstone is the portfolio evidence you take into applications. Live sessions run in the UK evening, which lands in the Riyadh evening, and every session is recorded.
Frequently asked questions
Is the training relevant to the SFDA's requirements? Yes. The SFDA's Guideline on Good Pharmacovigilance Practices is organised into the same modules as EU GVP, which is the framework the programme teaches. The SFDA does not approve individual training courses; what it asks of a QPPV is pharmacovigilance training certificates and qualifications, and what employers ask of you is evidence that you can do the work. The programme gives you both.
Can I take the programme from Riyadh, Jeddah or Dammam? Yes. Sessions are live in the UK evening, which falls in the Saudi evening, so they fit around a working day. Every session is also recorded.
Do I need industry experience before I start? No. The programme is built for healthcare professionals moving into industry for the first time. Your clinical background is the starting point, not a gap.
What is the difference between a QPPV and a Deputy QPPV in Saudi Arabia? Under the SFDA guideline, each marketing authorisation holder must have one local Qualified Person for Pharmacovigilance, working full time and resident in the Kingdom, who is accountable for the local pharmacovigilance system. It must also have a Deputy QPPV, also resident in the Kingdom and preferably a Saudi citizen, who covers the QPPV's responsibilities when needed. Both are senior roles reached after experience in case processing and aggregate reporting.
Is the programme delivered in English? Yes. Industry pharmacovigilance in Saudi Arabia operates in English, and the SFDA publishes its pharmacovigilance guideline in English.
How does this connect to Vision 2030? The National Biotechnology Strategy targets around 11,000 quality jobs by 2030 across vaccines, biomanufacturing, genomics and plant optimisation. Every medicine those sectors produce or market carries pharmacovigilance obligations under the SFDA guideline. Trained pharmacovigilance professionals are part of the workforce that strategy depends on.
If pharmacovigilance in Saudi Arabia is the direction you want, the next step is a 30-minute fit call.
Speak directly with Dorothy about your background, your timeline, and how the programme prepares you for industry drug safety roles in the Kingdom.
Book a fit call with Dorothy →